Potential urine test for bladder cancer that is minimally invasive A urine test based on RNA made by researchers at Stanford Medicine and other institutions may be able to improve the detection of bladder cancer without an invasive test just to get a sample. The experimental test, called uRARE-seq, detected localized bladder cancer with 95% sensitivity at 90% specificity in a 683-sample study. The research was published October 2, 2026, in Nature Medicine.
What Is the New Test for Bladder Cancer?
With the new test, scientists analyze cell-free RNA fragments in urine, which can carry biological signals emitted by cells in the urinary system, including urine cancer cells.
While typical urine cytology looks at cells under a microscope, uRARE-seq looks for a pattern of gene activity to detect a signal linked to bladder cancer. A customized gene panel was developed to separate signals from cancerous cells from normal signals seen in healthy urine.
The new method may have the potential to enable doctors to find cancer, define it and also follow-up after treatment.
What Did the Study Discover?
Researchers assessed uRARE-seq on urine samples from bladder cancer patients and noncancer individuals. The report found 95% sensitivity at 90% specificity to detect localized bladder cancer.
The sensitivity of a test is the proportion of people who have the disease that are correctly identified by the test. The specificity of a test is the proportion of people without the disease that are correctly identified by the test.
In another analysis, the team compared uRARE-seq against other urine tests. They found that in 93 urine samples, the new technique identified 89 cases of bladder cancer, while the cell detection test identified only 32. The new test, therefore, seems better at detecting bladder cancers that standard urine tests may overlook.
Nevertheless, these findings from research populations do not imply that the test is ready to screen the general population.
Could the Test Help After Cancer Treatment?
Another significant discovery was that the test had the ability to detect the molecular evidence of cancer when it was still present after surgery or treatment.
The team looked at whether RNA signals in urine might allow them to identify the patients who responded to BCG immunotherapy, as opposed to those who didn’t.
This method could someday allow doctors to track how patients are doing and make better decisions about follow-up. More forward-looking studies are needed before the test can be used with confidence to guide everyday treatment decisions.
Why Is Early Bladder Cancer Detection Important?
Bladder cancer occurs when cells in the lining of the bladder start to grow abnormally. The most common symptoms of bladder cancer are blood in the urine, increased frequency of urination, pain while urinating and ongoing pain in the bladder area.
Any instance of blood in urine should be checked by a doctor even if it occurs only once, or if there is no pain associated with it, as these symptoms may result from anything other than cancer, such as kidney stones or infections of the urinary tract.
Earlier detection, more accurate detection can assist doctors in investigating any suspicious symptoms and providing treatment.
What Are the Limitations of the New Test?
While the findings are encouraging, uRARE-seq is an experimental technology. The team pointed out that additional studies with bigger numbers of patients and clinical centres will be needed to verify uRARE-seq’s performance and to evaluate its clinical value.
The sensitivity and specificity reported here should not be understood to mean that the test can replace cystoscopy, imaging or other diagnostic procedures. Neither should they be taken to mean that the test is suitable for population-wide screening.
Conclusion
The new uRARE-seq urine test could lead to an effective way of detecting the disease and helping doctors understand if it’s still present after treatment.
While the sensitivity reported in the study is promising, more clinical testing is needed before this test can be implemented in routine medicine. Individuals who notice blood in their urine, or have ongoing urinary symptoms, should always see their doctor.
Medical disclaimer: This article is for information only. It should not be considered a substitute for professional medical advice.
